The research, led by Helena D. Hopson and Ellen M. Leffler of the University of Utah School of Medicine together with Sandrine E. Nsango of the Centre Pasteur du Cameroun and colleagues, focused on a question that has long been underexplored: what happens to the parasite’s genotype in asymptomatic infections? Most previous work on parasite adaptation to sickle haemoglobin examined children who were visibly sick with malaria. But in regions of intense transmission, a large share of infections produce no fever or other symptoms at all, and these silent infections are a major reservoir that keeps transmission going. Understanding whether the parasite’s sickle-associated alleles persist in these quiet infections offers a window into how the host-parasite relationship is actually playing out on the ground.

To answer it, the team conducted a cross-sectional survey of 2,246 healthy schoolchildren in the Mfou region of Cameroon, an area of about 3,300 square kilometres near the capital Yaoundé where malaria transmission is high. Samples were collected across three high-transmission seasons, spanning October to December 2022, April to May 2023, and November to December 2023, from eleven villages with individual sample sizes ranging from 6 to 638 children. The researchers genotyped each child for the human HbS variant and, using multiplexed amplicon deep sequencing, characterised the parasite genotypes in the blood samples, including the parasite loci known as Pfsa1 and Pfsa3, which carry alleles previously associated with sickle haemoglobin in studies of symptomatic disease.

The first key result was, in a sense, a negative finding. Children with the heterozygous sickle cell trait, genotype HbAS, and children with two normal haemoglobin copies, genotype HbAA, showed similar rates of asymptomatic infection. Out of the schoolchildren surveyed, 1,701 carried asymptomatic Plasmodium falciparum infections that could be genotyped. This means that sickle cell trait does not appear to prevent infection altogether in this setting; carriers are being infected at rates comparable to their non-carrier peers. The protection that HbS confers is therefore not a simple wall against the parasite, at least not against the parasite populations circulating in Mfou.

However, the composition of those infections differed dramatically by host genotype. The HbS genotype was strongly associated with parasites carrying the sickle-associated alleles, designated Pfsa-positive, at both the Pfsa1 and Pfsa3 loci. In other words, among children carrying one sickle haemoglobin copy, the parasites they harboured were significantly enriched for these specific variants, indicating a selective advantage for the Pfsa-positive alleles specifically within HbAS hosts. The association held up across villages and seasons, and additional analyses showed that HbS carriers had lower complexity of infection, meaning fewer distinct parasite genotypes per person, and lower parasitaemia, meaning fewer parasites in the bloodstream, compared with HbAA children.

These parasite alleles were first identified in a 2022 Nature study by Gavin Band and colleagues, who showed that the protective effect of sickle haemoglobin against symptomatic malaria depends on the parasite’s own genotype. Parasites carrying Pfsa-positive alleles appear to partially overcome HbS-mediated protection, which is why they are overrepresented among infections that make HbAS carriers sick. The new Cameroon study extends that logic backwards in the disease course: even before any symptoms appear, the host’s haemoglobin genotype is already shaping which parasite genotypes can establish and persist. The selective pressure exerted by sickle cell trait is visible in the silent reservoir of infection, not just in the clinic.

The authors interpret these findings through the framework of resistance and tolerance, two distinct biological strategies for dealing with infection. Resistance mechanisms reduce the number of parasites in the host, while tolerance mechanisms limit the damage caused by a given parasite burden without reducing the burden itself. Previous work has suggested that sickle haemoglobin acts through both routes: laboratory studies going back to 1978 showed impaired parasite growth in sickle trait red blood cells, driven in part by oxygen-dependent growth inhibition, while a 2011 Cell paper by Ferreira and colleagues argued that sickle haemoglobin confers tolerance to infection. The new data suggest that HbS protects against Pfsa-negative parasites before symptoms appear, consistent with a resistance effect, while the enrichment of Pfsa-positive parasites in asymptomatic carriers hints that these variants may contribute to the lower rates of symptomatic disease observed in HbAS individuals, a pattern more consistent with tolerance.

There is also a striking population-genetic detail in the study. The Pfsa1 and Pfsa3 loci showed strong inter-chromosomal linkage disequilibrium, meaning the sickle-associated alleles at the two loci tend to be inherited together on different chromosomes far more often than chance would predict. This non-random association suggests that the combination of Pfsa-positive alleles at both loci functions as a coordinated adaptation, and that recombination has not yet broken it apart in the Cameroonian parasite population. Such structure in a recombining parasite genome is a signature of recent or ongoing selection, consistent with the idea that P. falciparum is actively evolving in response to the sickle cell variant in human populations.

The broader implication is that the classic red-queen narrative of malaria and sickle cell is more accurately described as a genuine two-sided co-evolution. The sickle cell mutation arose in African populations and was driven to high frequency by the enormous mortality toll of falciparum malaria; recent work suggests rainforest hunter-gatherers acquired the mutation as recently as the Late Pleistocene. But the parasite, with its enormous population sizes and rapid generation times, has not stood still. Alleles that partially mitigate sickle-mediated protection have arisen and spread, and the new study demonstrates that this adaptation is detectable in the everyday, symptomless infections that sustain transmission between seasonal peaks. Host genotype and parasite genotype are locked in a reciprocal dance, and neither side’s moves can be understood in isolation.

For public health, the findings carry practical weight. Asymptomatic infections are increasingly recognised as the silent engine of malaria transmission, persisting through dry seasons and fuelling resurgent outbreaks even where control measures reduce clinical disease. If the parasite genotypes that dominate these reservoirs differ systematically by host haemoglobin status, then surveillance and intervention strategies may need to account for host genetics when interpreting parasite population structure. The study’s data, including human and parasite amplicon sequence reads deposited in the NCBI Sequence Read Archive under BioProject PRJNA1503656, and its analysis code released on GitHub, provide a resource for such efforts. What emerges is a refined view of a celebrated evolutionary story: sickle haemoglobin does protect against malaria, but the protection is a shifting, genotype-specific equilibrium, negotiated afresh by every parasite lineage that encounters a carrier’s red blood cells.

Subject of Research: How sickle cell haemoglobin genotype shapes Plasmodium falciparum parasite genotypes in asymptomatic malaria infections

Article Title: Sickle cell haemoglobin status shapes malaria parasite genotype in asymptomatic infections

Article References: Hopson, H. D., Herbert-Mainero, A., Bouopda-Tuedom, A. G., Nanssong-Vomo, C. T., Tumamo Fotso, B., Kiam, B. C., Ibrahima, I., Onguene, C., Abate, L., Omelianczyk, R. I., Evans, H. D., Horton, L. E., Band, G., Lamb, T. J., Ayong, L. S., Nsango, S. E., & Leffler, E. M. (2026). Sickle cell haemoglobin status shapes malaria parasite genotype in asymptomatic infections. Nature Microbiology. https://doi.org/10.1038/s41564-026-02502-4

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02502-4

Keywords: sickle cell trait, HbS, malaria, Plasmodium falciparum, asymptomatic infection, Pfsa alleles, host-parasite coevolution, genetic association study, Cameroon, disease tolerance, parasite genotype, Nature Microbiology

A research team led by Carolyn Williamson of the University of Cape Town, together with Penny L. Moore of the University of the Witwatersrand and James I. Mullins of the University of Washington, set out to answer a question that therapeutic trials cannot cleanly address: what happens to viral evolution when a broadly neutralizing antibody is already circulating in the blood at the moment of transmission? In chronic infection, resistance can emerge from archived reservoir viruses that carry pre-existing mutations, muddying any interpretation of cause and effect. In the AMP setting, by contrast, participants acquired HIV while receiving either VRC01 or placebo, and the virus that founded each infection was typically a single, genetically homogeneous lineage. That low diversity at transmission creates a high theoretical barrier to escape, because the virus must generate and select new mutations from a very narrow starting point. The trials therefore offered a uniquely clean window on de novo escape under defined antibody pressure.

The team focused on 47 participants who had acquired single-lineage infections with viruses that were sensitive or only intermediately resistant to VRC01, defined by an IC80 neutralization titre of 3 micrograms per millilitre or less. Twenty-three came from the Africa trial and 24 from the Americas trial, distributed across 21 placebo recipients, 15 low-dose recipients and 11 high-dose recipients. From each participant, the researchers analysed envelope sequences from two early timepoints, the first a median of just 18 days after the estimated date of acquisition. In total, 11,730 previously generated env sequences were examined, with a median of 108 sequences per participant per timepoint, generated using a Pacific Biosciences single-molecule real-time platform with unique molecular identifiers to ensure accuracy. This depth matters enormously: variants circulating at frequencies of one percent or lower would be invisible to conventional sequencing with around 20 reads, yet such low-frequency mutants are precisely where resistance begins.

To detect escape, the investigators tracked amino acid changes over time at 34 positions within the VRC01 epitope, using two complementary approaches. Escape logograms compared the amino acid composition at the second timepoint against the consensus of the founder lineage at the first, while maximum-likelihood phylogenetic trees paired with highlighter plots visualized which sequences had diverged and which mutations travelled together. Variant sites appeared in 18 of the 47 participants, and the pattern was strikingly asymmetric. Eleven variant sites were observed exclusively in VRC01 recipients and only one exclusively in placebo recipients, while three appeared in both groups. In the Africa trial, variant sites were significantly more common among treated participants, appearing in 9 of 13 VRC01 recipients versus 2 of 10 placebo recipients, and when the rate of change in variant frequency per day was pooled across trials, the high-dose group showed a significantly faster rate than placebo.

Identifying a variant site, however, is not the same as proving escape. To establish causality, the team used site-directed mutagenesis to introduce each observed amino acid change into a pseudovirus clone carrying the participant’s own transmitted founder envelope, then measured neutralization sensitivity in the standard TZM-bl assay. A change was classified as an escape mutation if it shifted the IC80 by more than threefold. The verdict was unambiguous: escape mutations emerged in 8 of 26 VRC01-treated participants, or 31 percent, compared with none of the 21 placebo recipients, a difference that held up statistically with a P value of 0.006. Notably, all eight escape cases were diagnosed within eight weeks of the last infusion, and no escape was seen in participants diagnosed after the trial endpoint, consistent with the idea that circulating drug levels were the selective force. Escape was also more frequent in the Africa trial, where all infections were subtype C, than in the Americas trial, where all were subtype B.

Structurally, the escape pathways converged on a familiar neighbourhood. The Loop D region of gp120 was the dominant hot spot, with mutations at residues 276, 279 and 280 detected in all eight participants, most often at positions 279 and 280. Additional mutations appeared in the N197 glycan motif and in the beta23 and V5 regions, including G458E, G459D and K460N. In two participants the virus appeared to toggle between alternative amino acids at the same residue, a pattern previously recognized as a signature of positive selection. Structural modelling onto a crystal structure of VRC01 bound to a subtype C gp120 offered a mechanistic explanation for several of these changes: the N280D substitution introduces a negative charge that electrostatically repels a negatively charged residue on the antibody light chain, while G458E and G459D insert bulky, charged side chains into a constrained binding interface. In contrast, D279A and D279G likely escape by shortening side chains and removing a negative charge, reshaping the contact surface in the opposite direction.

Perhaps the most clinically consequential finding concerns cross-resistance. The researchers tested 17 pseudovirus mutants against a panel of ten broadly neutralizing antibodies, including VRC01-class antibodies such as 3BNC117, VRC_CH31, VRC01.23LS and VRC07-523LS, as well as non-VRC01-class CD4 binding site antibodies N6, 1-18 and CH235.12, with PG9 and 10E8v4 as outgroup controls targeting the V2 apex and membrane-proximal external region. Pairwise correlations computed with random-effects generalized linear models showed that most VRC01-class antibodies clustered tightly with VRC01, meaning that escape from one largely compromised the others. Yet two antibodies stood apart. N6, whose distinct binding angle likely explains its resilience, was only moderately correlated with VRC01, and the highly potent antibody 1-18 was the most robust of all, retaining IC80 values below 1 microgram per millilitre against 75 percent of the VRC01 escape mutants and a median IC80 below 0.1 micrograms per millilitre overall. Intriguingly, some Loop D mutations actually increased sensitivity to CH235.12, by as much as 44-fold, illustrating that escape from one antibody can come at the cost of vulnerability to another.

Double mutations told an equally instructive story about how resistance compounds. In one participant, the N197T/K460N combination conferred more than tenfold greater resistance than either single mutation alone, pushing the IC80 above 25 micrograms per millilitre. In another, the double mutants N280D/G459D and D279A/G459D produced 42-fold to 76-fold increases in resistance relative to the single mutants. The effects were also strongly context dependent: the same N280D mutation conferred resistance to six of eight antibodies in one viral backbone, four of eight in another, and only one of eight in a third, underscoring that the genetic background in which a mutation arises shapes its antigenic consequence. One participant also carried an A318T substitution that co-evolved with the G458E escape mutation, possibly compensating for the fitness cost of inserting a charged, bulky residue into the CD4 binding interface.

That fitness cost is the study’s most reassuring thread. When the team searched 8,452 group M HIV-1 sequences from the Los Alamos National Laboratory database, every escape amino acid except K460N was present at a frequency below one percent of circulating viruses, and the K460N change was simply a reversion from one uncommon residue to a more common one. The rarity of these mutations in the wild suggests they impose a replicative penalty on the virus, which may explain why they have not spread despite the antibody’s clinical use. Whether resistant variants could persist and transmit if VRC01 exposure were more sustained remains an open question, and the authors argue that long-term surveillance of these variants in treatment and prevention cohorts should be a priority.

The broader implications reach directly into the design of next-generation prevention. Because 40 percent of the escape mutations detected here were present at frequencies of two percent or lower, standard sequencing approaches would have missed most of them, a gap the authors say argues for incorporating deep sequencing into resistance screening for prevention and cure trials. More strategically, the findings demonstrate that antibody-mediated pre-exposure prophylaxis, like antiretroviral-based PrEP before it, can select for viral escape after infection, and that escape pathways are common, convergent and predictable. As newer broadly neutralizing antibodies with greater potency, broader coverage and longer half-lives enter clinical evaluation, the map of VRC01’s vulnerabilities provides a blueprint: antibodies such as N6 and 1-18, which shrugged off these escape mutations, point toward combinations that could raise the evolutionary barrier and keep HIV’s adaptability in check.

Subject of Research: Viral escape from the broadly neutralizing antibody VRC01 during HIV prevention trials

Article Title: Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

Article References: Williamson, C., Curry, L., Mkhize, N. N., Giorgi, E. E., Magaret, C. A., Lambson, B. E., Bhebhe, S., Kaldine, H., Moyo-Gwete, T., Rolland, M., Rossenkhan, R., Garcia, N. M. G., Moodley, C., Yssel, A., Huang, Y., Marsden, A. A., Reeves, D. B., Mayer, B. T., Bumgarner, R. E., … Mullins, J. I. (2026). Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials. Nature Microbiology. https://doi.org/10.1038/s41564-026-02467-4

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02467-4

Keywords: HIV, VRC01, broadly neutralizing antibodies, viral escape, AMP trials, HIV prevention, CD4 binding site, Loop D, deep sequencing, viral evolution, antibody-mediated prophylaxis, Nature Microbiology

The finding centres on a behaviour called cell traversal. When an infected mosquito bites a host, it injects sporozoites, the parasite’s liver-infective stage, into the skin. These slender, motile parasites enter the bloodstream and travel to the liver, where they must cross the sinusoidal barrier to reach their target hepatocytes. Before doing so, they repeatedly breach the membranes of host cells, glide through the cytoplasm and exit without establishing a lasting infection. This process, first described more than two decades ago, has long been viewed mainly as a mechanical necessity for the parasite’s journey. The new work shows it is also a powerful immunological event, one that shapes the composition and potency of the T cell response that whole-sporozoite vaccines depend upon.

Whole-sporozoite vaccines, which use radiation-attenuated, genetically attenuated or chemically attenuated parasites, are the only malaria vaccine strategy that has consistently achieved sterile protection—the complete prevention of infection—in both rodent models and human trials. This stands in sharp contrast to the licensed subunit vaccines RTS,S and R21, which target the circumsporozoite protein and reduce clinical disease but do not reliably stop infection, a key requirement for eradication. The prevailing assumption has been that whole-sporozoite protection depends primarily on the immunizing parasites infecting hepatocytes and undergoing prolonged intrahepatic development, thereby exposing the host to a broad repertoire of parasite antigens. The Lisbon team set out to test whether that assumption told the whole story.

To do so, the researchers compared wild-type Plasmodium berghei parasites with genetically engineered lines unable to perform cell traversal. One line lacked the SPECT1 protein, a sporozoite microneme component essential for breaching host cell membranes; a second, newly generated line lacked the perforin-like protein PLP1, which serves a similar function. Because traversal-deficient parasites are also less infectious, the team carefully calibrated inoculum sizes, establishing that a fifteen-fold higher dose of the mutant parasites produced liver infection loads equivalent to those achieved with the standard dose of wild-type parasites. Crucially, the mutants retained normal gliding motility and, once inside hepatocytes, developed normally, meaning any difference in vaccine efficacy could be attributed specifically to the loss of traversal rather than to a general defect in parasite fitness.

The results were striking. In a standard prime–boost–boost immunization regimen with radiation-attenuated sporozoites, roughly 82.5 percent of mice vaccinated with wild-type parasites were completely protected against subsequent challenge with infectious parasites, showing no blood-stage infection over a twelve-day monitoring period. Among mice vaccinated with the traversal-deficient parasites, however, protection collapsed: none of the SPECT1-deficient cohort and only about 13 percent of the PLP1-deficient cohort remained parasite-free. The pattern held even under immunization regimens that allowed extended or complete intrahepatic development, using infectious sporozoites under azithromycin or chloroquine chemoprophylaxis. Even when the mutant parasites replicated fully in the liver, they failed to confer sterilizing immunity. Conversely, parasites lacking the P36p protein—which cannot develop substantially in the liver but retain full traversal ability—protected mice just as effectively as wild-type parasites, with comparable durability over nearly seven months.

These findings decouple protection from productive intrahepatic development and reposition parasite behaviour as a central immunogenic determinant. But what mechanism underlies this effect? The team found that antibody responses were largely intact in mice vaccinated with traversal-deficient parasites: anti-sporozoite IgG levels rose comparably in all immunized groups, regardless of the parasites’ ability to traverse cells or develop in the liver. The deficit lay specifically in cellular immunity. In C57BL/6 mice, a strain in which protection depends on CD8 T cells clearing infected hepatocytes, traversal-deficient vaccination failed to generate the protective T cell response. When the researchers depleted CD8 T cells from wild-type-vaccinated C57BL/6 mice before challenge, protection vanished entirely, confirming the dominant role of these cells. In BALB/c mice, a strain that mounts strong antibody-mediated responses, both wild-type and traversal-deficient parasites conferred full protection, and CD8 T cell depletion had no effect—demonstrating that traversal matters precisely when protection relies on T cells.

Using high-parameter spectral flow cytometry and unsupervised clustering of liver leukocytes, the researchers then identified the specific cell population affected. Mice vaccinated with traversal-competent parasites showed a marked expansion of CD8 tissue-resident memory T cells, or TRM cells, in the liver—cells bearing the hallmark markers CD69 and KLRG1-negative status, along with high CXCR3 and CXCR6 expression and elevated CD127 and PD-1, consistent with long-lived, antigen-experienced residents. These cells were significantly under-represented in mice vaccinated with traversal-deficient parasites. Liver-resident memory CD8 T cells are known to form a front-line defence against malaria liver-stage infection, and their presence correlates with durable protection. The team also found that these cells persisted in the liver at least seventy-five days after priming, matching the window of robust protection observed in challenge experiments.

Delving deeper into antigen specificity, the researchers examined CD8 TRM cells targeting two well-characterized Plasmodium epitopes: PbTRAP, a thrombospondin-related protein expressed mainly at the sporozoite stage and shed during parasite locomotion, and PbRPL6, a ribosomal protein associated with intrahepatic development. Vaccination with traversal-competent parasites expanded TRM cells specific for both epitopes. Traversal-deficient vaccination, however, selectively compromised the TRAP-specific population while leaving RPL6-specific cells detectable, albeit reduced. This selective loss suggests that traversal amplifies responses against sporozoite-derived antigens in particular, plausibly by disseminating parasite material across many host cells early in infection. Notably, the defect was not explained by reduced TRAP shedding during gliding motility, and splenectomy experiments showed that while splenic priming contributes to the overall magnitude of the hepatic TRM pool, traversal at the site of infection independently shapes its antigen-specific composition.

The implications for vaccine design are substantial. Current efforts have focused overwhelmingly on identifying optimal antigens and epitopes; this study argues that the dynamic interactions between the parasite and host tissues deserve equal attention. Next-generation whole-sporozoite vaccines might be engineered or selected for enhanced traversal motility to promote stronger, longer-lasting liver-resident CD8 TRM responses. Alternatively, the molecular and inflammatory cues generated by cell traversal could inspire adjuvants that mimic its immunostimulatory effects, potentially benefiting subunit vaccines that currently rely on humoral immunity alone. The findings may also help explain why responses to whole-sporozoite vaccines in humans are heterogeneous, with some vaccinees failing to achieve sterile protection for reasons that remain poorly understood.

There is also an evolutionary dimension worth pondering. It may seem paradoxical that a parasite evolved a behaviour that ultimately arms the immune system against it. The authors suggest this represents a trade-off: under natural transmission, only a small number of sporozoites reach the liver, and traversal is essential for crossing the skin and sinusoidal barriers to establish infection at all. The immunostimulatory consequences only become decisive during vaccination, when artificially high parasite doses amplify exposure to traversal-dependent cues. Whether this principle—harnessing parasite behaviour rather than merely parasite antigens—can be translated into human vaccines remains an open question, particularly since liver-resident T cells are difficult to sample directly in people. Still, the study marks a conceptual shift: for malaria, how a parasite moves through its host may matter as much as what it is made of.

Subject of Research: The role of Plasmodium sporozoite host cell traversal in inducing sterilizing CD8 T cell-mediated immunity after whole-sporozoite malaria vaccination

Article Title: Host cell traversal by Plasmodium parasites drives sterilizing T cell-mediated immunity following immunization

Article References: Rodrigues, A., Mendes, A. M., Gonçalves, R., Nunes-Cabaço, H., Marques, S., Valente-Leal, N., Gomes da Costa, D., Ferreira, C., Veldhoen, M., Prudêncio, M., Mota, M. M., & Chora, Â. F. (2026). Host cell traversal by Plasmodium parasites drives sterilizing T cell-mediated immunity following immunization. Nature Microbiology. https://doi.org/10.1038/s41564-026-02477-2

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02477-2

Keywords: malaria, Plasmodium, sporozoites, cell traversal, T cells, tissue-resident memory T cells, vaccines, liver-stage immunity, CD8 T cells, radiation-attenuated sporozoites, immunology, Nature Microbiology

The research, published in Nature Microbiology by a team led by scientists at the University of Utah Health, the University of Douala, and the Centre Pasteur du Cameroun, combined large-scale genetic analysis of human blood samples with equally detailed sequencing of the malaria parasites infecting them. Working in Mfou, a malaria-endemic community in Cameroon, the researchers analyzed genetic material from more than 2,000 people, capturing both symptomatic infections and the far more numerous asymptomatic ones. What emerged was a picture of host-pathogen interaction far more intricate than the conventional narrative of a human mutation simply blocking parasite growth inside red blood cells.

The central discovery is striking: people who carry the sickle cell variant are almost exclusively infected by a genetically distinct variety of malaria parasites. In other words, the parasite population infecting a person is not random with respect to their hemoglobin genotype. Parasites with one genetic signature dominate infections in carriers of the sickle cell trait, while parasites with a different genetic makeup are more commonly found in people without the variant. This pattern held not only in the rare cases where carriers fall ill, but also — and crucially — in the vast pool of asymptomatic infections that make up most malaria transmission in endemic settings.

Asymptomatic infections are the quiet majority of the malaria burden. In the Mfou study population, roughly three-quarters of apparently healthy participants carried malaria parasites in their blood without showing any symptoms. These silent reservoirs are less visible to clinics and surveillance systems than the fevers and hospitalizations of clinical malaria, but they sustain transmission and represent the environment in which the parasite and its human host negotiate their long evolutionary standoff. By extending their analysis to this hidden majority, the researchers uncovered a relationship that earlier work focused on symptomatic disease could not fully reveal.

Perhaps the most consequential finding concerns infection rates versus disease rates. People carrying the sickle cell variant become infected with malaria parasites at roughly the same overall frequency as people without the variant — they simply tend to harbor a different genetic variety of the parasite. Yet carriers are about ten times less likely to develop harmful, symptomatic disease. This observation upends a tempting earlier hypothesis. When the distinct parasite strain was first identified in symptomatic carriers of the sickle cell trait, scientists speculated that it might be a kind of superbug, unusually adept at breaking through the carriers’ defenses and causing illness. The new data suggest nearly the opposite: the biological properties of this parasite variety may themselves contribute to the carriers’ protection, rather than undermining it.

That reframing matters because it changes where researchers should look for answers. The classical explanation for sickle cell trait protection centers on the human host: the altered hemoglobin environment inside red blood cells is thought to stress the parasite, shorten the lifespan of infected cells, and impair the parasite’s ability to replicate and to cause the sequestration in small blood vessels that underlies severe disease. The new findings do not overturn that biology, but they add a second dimension. If the parasites capable of establishing infection in sickle cell trait carriers are systematically different from those infecting other people, then part of the protective effect may lie in the parasite’s own characteristics — how virulent it is, how efficiently it multiplies, or how readily it triggers the inflammatory cascades that produce symptoms.

Sandrine Nsango, associate professor of molecular biology at the University of Douala, researcher at the Centre Pasteur du Cameroun, and one of the senior authors of the study, framed the result as evidence of a two-way evolutionary conversation. The sickle cell mutation, she noted, is one of the clearest examples of how an infectious disease can shape human evolution, but the findings suggest that humans also shape the evolution of the parasite in return. The parasite lineages that can survive in the red blood cells of trait carriers are, in effect, a selected subset of the parasite population — filtered by generations of host genetics. Understanding that filtering process, she argued, may help scientists anticipate how malaria parasites adapt in the future and design more effective strategies for malaria control.

Ellen Leffler, assistant professor of human genetics at University of Utah Health and the study’s other senior author, described the discovery as something that had been hiding in plain sight. Researchers have studied the association between sickle cell trait and malaria protection for more than half a century, but the parasite’s side of the story required tools that only became practical recently: high-throughput DNA sequencing capable of characterizing whole parasite populations directly from human blood samples. As Leffler put it, people have been examining this association for a long time, but you have to be able to ask the parasite for it to tell you this. The new sequencing approach effectively did exactly that, revealing that the genotype of the infecting parasite is a variable that previous study designs largely ignored.

The implications extend beyond evolutionary theory into practical medicine and public health. If specific parasite genotypes are associated with asymptomatic carriage in sickle cell trait carriers, then parasite genetics could become a tool for tracking transmission, identifying which parasite lineages circulate in a community, and monitoring how the parasite population shifts under the pressure of interventions such as bed nets, drugs, and vaccines. Leffler emphasized that the work opens a new dimension for understanding what determines the outcome of an infection, and expressed hope that it will lead to a deeper biological understanding of the parasite and of this co-evolutionary system — one she described as quite unique in humans — and ideally to practical new strategies for tracking or treating infections.

The study also serves as a reminder of how much remains unknown about one of biology’s most famous examples of natural selection. The sickle cell allele’s protective effect was first proposed in the 1950s and has since become a textbook staple, yet the full mechanism has never been a single tidy story. Red blood cell physiology, immune responses, and parasite biology all appear to contribute, and disentangling them requires studying real populations in endemic regions, where people are repeatedly exposed to genetically diverse parasites over a lifetime. The Mfou cohort, sequenced at the level of both human and parasite genomes, offers exactly that kind of window. The work was supported by the Fondation Pierre Fabre under the IMPAS project and by the American Heart Association, and the authors report no competing interests. As malaria control efforts worldwide confront drug resistance and shifting parasite populations, the message of this study is clear: to understand why some people are protected, scientists must listen not only to the human genome but to the parasite’s as well.

Subject of Research: How sickle cell haemoglobin status shapes the genotypes of malaria parasites in asymptomatic human infections

Article Title: Distinct malaria parasites “hidden in plain sight” may contribute to human disease protection

Article References: Distinct malaria parasites “hidden in plain sight” may contribute to human disease protection. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: malaria, sickle cell trait, Plasmodium, hemoglobin, genomics, asymptomatic infection, coevolution, Cameroon, parasite genetics, Nature Microbiology, human evolution, disease protection

The study, published in Nature Microbiology, focused on a long-standing puzzle in human microbiome research. Across the globe, human gut communities fall into recognizable patterns. In industrialized populations, members of the bacterial family Bacteroidaceae tend to dominate. In many non-industrialized populations, by contrast, bacteria of the family Prevotellaceae are far more common, including the species Segatella copri, formerly known as Prevotella copri. A plant-rich diet has long been discussed as a possible explanation for these regional differences, since Prevotellaceae are often associated with the consumption of complex plant carbohydrates. But diet alone, the new work suggests, cannot account for the pattern.

“We wanted to understand which factors actually influence the competition between these bacteria in the gut,” says Dr Caroline Tawk, one of the first authors of the study and, until recently, a researcher in Strowig’s department. Supported by a joint fellowship from the HZI and EMBL, she spent several months at EMBL in Heidelberg, where she developed a highly parallelized experimental setup capable of testing a wide range of dietary components at once. This high-throughput approach allowed the team to move beyond single-species, single-substrate experiments and instead examine how nutrients play out within a realistic bacterial community.

The experimental design was deliberately rigorous. The researchers first assembled a defined community of 21 human gut bacteria, a simplified but reproducible stand-in for the far more complex ecosystem of the human intestine. Against this community, they tested 94 dietary components, with a particular focus on complex carbohydrates and vitamins, the classes of molecules most likely to shape competition among fiber-degrading microbes. The outcome was striking: more than half of the tested components promoted the growth of S. copri within the community. On the surface, this seemed to confirm the idea that plant carbohydrates directly favor Prevotellaceae over their Bacteroidaceae rivals.

A closer look at one carbohydrate, however, overturned that assumption. The team examined arabinan, a complex sugar found in plant cell walls, in particular detail. S. copri can directly utilize arabinan, but so can other members of the Bacteroidaceae. That meant a direct nutritional benefit could not explain why S. copri expanded in the community while its competitors did not. Something other than simple access to the substrate was tipping the balance, and the researchers set out to identify what it was.

The answer emerged when the team simplified the system. “When we brought S. copri and Bacteroidaceae together without the other members of the gut community, S. copri did not prevail despite the presence of arabinan,” Tawk explains. “Only when we added Escherichia coli to the mix, the competitive balance shifted in favor of S. copri.” This was a pivotal observation. E. coli, a member of the family Enterobacteriaceae, was not merely a passive bystander; its presence was required for S. copri to gain the upper hand. Other Enterobacteriaceae tested, including Klebsiella and Salmonella, also supported S. copri under certain conditions, indicating that the effect is a family-level trait rather than a quirk of a single strain.

Even more intriguing was what happened when the researchers used strains of E. coli that cannot metabolize the monosaccharides released during arabinan breakdown. These metabolically impaired strains still supported the growth of S. copri. “We therefore assume that the presence of the sugars—as signal molecules, rather than their consumption by E. coli—may be sufficient to explain the observed supportive effect,” says Dr Youssef El Mouali, the other first author of the study. The exact molecular mechanism, however, remains unknown. The finding hints at a form of cross-species communication in which sugars liberated from dietary fiber act as signals that reconfigure competitive interactions, rather than simply serving as food. Untangling that signaling pathway is now a priority for the group.

Laboratory models, however convincing, always leave open the question of whether the phenomenon operates in real people. To address this, the HZI team partnered with researchers from the University of Trento to analyze publicly available microbiome data from approximately 1,000 healthy adults. As expected, S. copri and Enterobacteriaceae were both more common and more diverse in datasets from non-industrialized populations. Crucially, within that group, a higher number of different Enterobacteriaceae species was associated with a higher proportion of S. copri. This correlation mirrors the laboratory experiments and suggests that the supportive relationship between Enterobacteriaceae and S. copri is not an artifact of defined communities in a flask, but a dynamic that also plays out in the human gut.

The broader implications reach into one of the most debated questions in microbiome science: why do interventions such as fiber supplementation or probiotics produce such variable results from person to person? The new findings offer a mechanistic explanation. A dietary component cannot be evaluated in isolation from the existing bacterial community, because its impact is mediated by the ecological web in which it lands. The same arabinan that helps S. copri flourish in one microbial context leaves it outcompeted in another. For clinicians and nutrition scientists, this means that predicting the outcome of a dietary change may require knowing not just what a person eats, but who else lives in their intestine.

“Our results show that the effect of a dietary component should not be considered in isolation from the existing bacterial community,” Strowig summarizes. “We need to clarify in further studies whether this knowledge can be used for personalized dietary or microbiome approaches.” If the underlying mechanisms can be pinned down, the ecological logic revealed by this study could inform strategies for deliberately reshaping gut communities, whether to establish bacteria associated with healthier metabolic profiles or to limit the expansion of unwanted ones. The work was supported by grants from the German Research Foundation (DFG), the RESIST Cluster of Excellence, and the program Amplifying Funds in Infection Biology. For now, the message is clear: in the gut, context is everything, and even the humblest fiber is only as influential as the microbes that surround it.

Subject of Research: How dietary fiber and Enterobacteriaceae jointly shape competition between dominant gut bacterial groups

Article Title: Dietary fiber does not act alone in the microbiome

Article References: Dietary fiber does not act alone in the microbiome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gut microbiome, dietary fiber, Segatella copri, Bacteroidaceae, Prevotellaceae, Enterobacteriaceae, Escherichia coli, arabinan, microbiome competition, personalized nutrition, Nature Microbiology, Helholtz Centre for Infection Research

The study, published in Nature Microbiology by Alexandre Persat’s Microbial Mechanics Lab in collaboration with Sangwoo Kim’s Mechanics of Soft and Biological Matter Laboratory, both at EPFL, reveals that the opportunistic pathogen Pseudomonas aeruginosa actively senses when it collides with neighboring cells and responds by reversing its direction of travel within seconds. This touch-based feedback loop allows the bacterial population to do something remarkable: stay highly organized where organization matters, such as at the advancing edge of a growing colony, while deliberately dissolving that order in crowded regions where it would otherwise trap individual cells. According to the authors, this shows that collective order in bacterial groups is not merely a passive consequence of physics but an actively regulated state that the cells themselves control.

The problem the bacteria face is one that anyone who has ever been stuck in a dense crowd will recognize. P. aeruginosa moves across surfaces using a form of motility that depends on physical contact with the substrate, and in dense communities the cells frequently line up and stream together in coordinated groups. These physical interactions between neighboring cells create alignment, and alignment creates order. But order has a downside. Individual cells embedded within a coordinated stream can become trapped inside the group, unable to turn away and strike out into new territory. For a bacterium, that inability to disperse is a serious handicap: it prevents the cell from finding fresh nutrients, and it hinders escape from crowded, structurally complex environments such as soil pores or the tissues of a host during infection.

Laure Le Blanc, the paper’s first author, explains the mechanism in simple terms. As the bacteria move across surfaces, they sense when they bump into neighbors, and in response they reverse direction within seconds. That rapid reversal is the key. Each collision acts as a piece of sensory information, telling the cell that its local environment is congested and that continuing straight ahead would be counterproductive. By reversing, the cell injects disorder into the collective motion, loosening the alignment that physical contact tends to create. Where collisions are rare, for example at the open frontier of a colony, the cells align strongly and move together toward unexplored space. Where collisions are frequent, the reversals accumulate and the group remains disordered and mobile. The population effectively uses touch to tune its own degree of collective organization from moment to moment.

To disentangle how individual collisions translate into group-level behavior, the team combined three complementary approaches: live microscopy to watch the bacteria in action, single-cell tracking to follow the trajectories of individual cells, and computer simulations to test how collision-driven reversals shape population dynamics. Crucially, they compared wild-type bacteria, which possess the full sensory machinery, with mutant strains that lack it. This side-by-side comparison allowed the researchers to isolate the specific contribution of collision sensing, rather than inferring it indirectly from the behavior of intact populations alone. By tracking individuals and analyzing overall group movement simultaneously, they could observe in real time how a microscopic bump between two cells rippled outward to reshape the behavior of the entire community.

The contrast between the two strains was striking. The researchers worked with a mutant lacking a gene critical for the bacterium’s normal motility pattern; the mutant always moves forward, even after colliding with other cells or with boundaries. When traveling alone, the mutants actually performed well, covering greater distances than their wild-type counterparts, since relentless forward motion pays off in empty space. But when moving together, the advantage evaporated. Without the ability to respond to collisions, the cells quickly became trapped in dense clusters, jamming against one another much like a crowd pressing into a blocked exit. The wild-type cells, by contrast, used each bump as information, reversing in crowded areas to keep the group fluid and exploratory, while maintaining tight alignment at the colony edge where open space invited coordinated advance.

The most dramatic demonstration came from an experiment that sounds almost whimsical: the researchers built micro-mazes, tiny obstacle-filled labyrinths, and released the two strains inside to see how they would navigate the confined, structured environment. The results were decisive. Only one percent of the collision-blind mutant bacteria managed to reach the maze exit within four hours. The wild-type cells, equipped with their touch-based navigation system, explored an average of ninety-two percent of the maze, and twenty percent of the cells eventually found the exit. In other words, the ability to feel a collision and reverse course transformed a population of microscopic wanderers into efficient problem-solvers capable of threading their way through a physical puzzle that stumped the mutants almost completely.

At the mechanistic level, the findings reframe what bacterial collectives are doing on surfaces. The classical picture treats alignment and streaming in dense bacterial groups as emergent physics, the inevitable result of cells pushing against one another as they crawl. The new work shows that P. aeruginosa actively modulates that physics, converting mechanical interactions into sensory input that feeds back onto individual behavior and, from there, onto the architecture of the whole population. The cells are, in effect, performing a computation: the frequency of collisions in their immediate surroundings encodes the local density of the crowd, and the reversal response reads that signal out as a behavioral decision. This allows the same population to display two very different collective states, ordered at the frontier and disordered in the interior, without any central coordination or chemical signaling between distant cells.

The implications extend well beyond basic microbiology. P. aeruginosa is a notorious opportunistic pathogen, and the researchers suggest that this collision-sensing mechanism may help the bacterium spread through host tissues and contribute to biofilm formation during human infections. Understanding how the cells regulate their collective organization could therefore inform new strategies for interfering with bacterial dispersal and biofilm development, both of which are major challenges in clinical settings where antibiotic-resistant infections are a growing concern. The discovery also carries a lesson for engineers. Robot swarms deployed in crowded or unknown environments face exactly the same trade-off between cohesion and exploration that bacteria face, and they often get stuck for precisely the reasons the mutant cells do. A simple rule, reverse when you bump into something, turns out to be a remarkably effective decentralized algorithm for keeping a swarm mobile, and it requires no central controller, no map, and no communication beyond the moment of contact itself.

What makes the study especially compelling is the way it connects scales. A single molecular event, a cell brushing against a neighbor, triggers a reversal within seconds; thousands of such events sculpt the shape and exploratory capacity of an entire colony; and in a maze, that collective behavior determines whether the population escapes or perishes. Persat’s framing of the question, drawn from fish schools, bird flocks, and human crowds, finds its answer in one of the simplest organisms on Earth: individuals in a group can balance coordination with exploration by using their own bodies as sensors. For bacteria, the crowded environment is not an obstacle to navigation but the very source of the information needed to navigate it. The bump in the crowd, it turns out, is the message.

Subject of Research: Mechanosensing of cell-cell collisions regulating collective navigation in Pseudomonas aeruginosa

Article Title: Bacteria use collisions to navigate crowded environments

Article References: Bacteria use collisions to navigate crowded environments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Pseudomonas aeruginosa, bacteria, mechanosensing, collective behavior, cell-cell collisions, twitching motility, biofilms, micro-mazes, EPFL, Nature Microbiology, robot swarms, bacterial navigation

Attenuated sporozoites, the infective stage of Plasmodium parasites injected by mosquitoes, have been tested as vaccines for decades because they provoke robust adaptive immunity that protects against subsequent challenge. The most advanced of these approaches, whole-sporozoite vaccines designed to protect through hepatic CD8 T cell immunity, have shown encouraging results in clinical trials. Yet a fundamental question has lingered: how do these parasites engage the innate immune system to license such potent T cell responses? Pattern recognition receptors such as Toll-like receptors and inflammasome sensors are the canonical gatekeepers of innate immunity, but their role in sporozoite immunogenicity has never been clearly defined.

To answer this, the team built what they describe as a reductionist system. They generated fluorescent GFP-expressing Plasmodium berghei and Plasmodium falciparum sporozoites, purified the parasites by flow cytometry directly from mosquito salivary glands, and sorted them onto mouse bone marrow-derived macrophages or human peripheral blood mononuclear cells. This allowed them to isolate the innate response to sporozoites from the confounding signals of mosquito saliva, blood-stage parasites, and other contaminants that complicate whole-organism studies. They then profiled the responding cells using bulk and single-cell RNA sequencing, capturing the transcriptional landscape of innate activation at high resolution.

The results were striking. Sporozoites did not induce the classical inflammatory programs associated with microbial pattern recognition. Instead, the transcriptional signature in macrophages and human monocytes resembled a cell wounding response, the program that cells mount when their plasma membrane is breached. This makes biological sense: sporozoites must traverse host cells as they migrate from the skin through the dermis to the liver, breaching the membranes of the cells they pass through before finally settling in hepatocytes. The parasites, in effect, leave a trail of wounded cells, and the immune system reads that trail as a danger signal.

The evidence for this interpretation came from a decisive genetic experiment. The researchers used sporozoites lacking SPECT1, a protein with a membrane attack complex-like domain that is essential for pore formation and cell traversal. These traversal-deficient parasites, which can still invade hepatocytes but cannot punch through intermediate cells, failed to activate bone marrow-derived macrophages in vitro. The wounding signature disappeared entirely when the pore-forming machinery was removed, demonstrating that the innate activation was not triggered by parasite molecules detected by conventional sensors but by the physical damage the parasite inflicts on host cells.

Importantly, the wounding response was independent of both inflammasome and Toll-like receptor signalling, the two most intensively studied pathways of innate immune activation. This rules out the standard explanation and points instead toward a distinct sensing modality. Previous work from other laboratories has shown that cells surviving sublethal plasma membrane injury mount a characteristic transcriptional response involving repair machinery and chemokine production, and the sporozoite-induced signature overlapped with these curated plasma membrane injury gene sets. The immune system, it appears, can detect the wound itself rather than the weapon that caused it.

The study then connected this innate sensing to the adaptive immunity that actually protects against malaria. In mice immunized with traversal-deficient irradiated sporozoites, the priming of protective CD8 T cell responses was markedly impaired compared with immunization using normal traversal-competent parasites. Given that CD8 T cells are the critical mediators of sterile immunity against the liver stage of malaria, this deficit is not a minor detail. It suggests that the wounding of host cells during traversal is not incidental damage but an essential adjuvant-like signal that the whole-sporozoite vaccine platform depends upon.

A further layer of the mechanism involves γδ T cells, an unconventional lymphocyte population that bridges innate and adaptive immunity. The researchers found that the sensing of cell traversal required γδ T cells, which are already known to support CD8 T cell responses against Plasmodium. Earlier work has shown that γδ T cells are required for the induction of sterile immunity during irradiated sporozoite vaccination, and recent studies have demonstrated that γδ T cell-derived IL-4 can initiate CD8 T cell immunity. The new findings place these cells squarely within the sensing pathway: they appear to translate the cell wounding signal into help for the CD8 T cells that will later eliminate infected hepatocytes.

The cross-species consistency of the results strengthens their significance. Human monocytes exposed to Plasmodium falciparum sporozoites showed an activation pattern that overlapped with the mouse data, including the plasma membrane injury signature, indicating that the mechanism is not a rodent-specific curiosity but likely operates in human malaria infection and vaccination. Single-cell RNA sequencing of human peripheral blood mononuclear cells revealed that multiple innate cell types respond to sporozoites, with the response distinguishable from that induced by blood-stage parasites, which instead triggered more conventional inflammatory programs.

For vaccine development, the implications are considerable. Subunit vaccines based on the circumsporozoite protein have struggled to achieve the high levels of protection seen with whole sporozoites, and this study offers a possible explanation: they lack the cell traversal signal that recruits γδ T cells and licenses potent CD8 T cell priming. Incorporating a wounding-mimetic adjuvant, or designing vaccine delivery strategies that reproduce the membrane injury signal, could help close that gap. Conversely, the findings caution that any attenuated sporozoite vaccine engineered to block traversal, however attractive from a safety standpoint, might sacrifice immunogenicity. As malaria continues to claim hundreds of thousands of lives each year, understanding why live sporozoites are such effective teachers of the immune system brings the field one step closer to a vaccine that can match that performance without a live parasite.

Subject of Research: Innate immune sensing of Plasmodium sporozoite cell traversal and its role in priming protective CD8 T cell responses

Article Title: Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses

Article References: Pohl, K. G., Gao, X., McGowan, J., Mukherjee, P., Le, S., Carreira, P., Ngo, C., Sutton, H. J., Brumhard, S., Hiller, A., Kelly, H. G., Liow, L., Lo, A., Henze, L., Loyal, L., Amino, R., Man, S. M., Beattie, L., Sander, L. E., & Cockburn, I. A. (2026). Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses. Nature Microbiology. https://doi.org/10.1038/s41564-026-02460-x

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02460-x

Keywords: malaria, Plasmodium, sporozoites, cell traversal, innate immunity, CD8 T cells, gamma delta T cells, vaccines, plasma membrane injury, Nature Microbiology, immunology, parasitology

The central problem the work addresses is a familiar one in phage therapy: lytic phages are remarkably effective at killing their bacterial targets in a dish, but their performance in the gut often falls short of expectations. The mammalian intestine is a crowded, chemically complex environment in which introduced phages can be diluted by gut transit, inactivated by changes in pH and bile, adsorbed by mucus and particulate matter, or simply outcompeted by the sheer density of resident microbes. Concentrations of phage that would rapidly clear a bacterial culture in vitro may never reach the threshold needed to suppress a pathogen in vivo, particularly when treatment begins before an infection has taken hold.

Prophylactic phage therapy—giving phages in advance of exposure to a pathogen—makes this problem especially acute. If phages are administered orally as free virus particles, they must survive passage through the stomach, persist in the intestinal lumen for an extended period, and remain at effective concentrations until the pathogen arrives. Because lytic phages only replicate when they encounter susceptible host bacteria, a prophylactically delivered phage that meets no target simply decays. The new study’s answer is to stop thinking of the phage as the delivered agent and start thinking of a bacterium as the delivery vehicle.

The researchers engineered bacterial strains to encode prophages in their genomes. A prophage is the integrated, dormant form of a temperate phage: its DNA is replicated along with the host cell’s chromosome and passed to daughter cells at division, effectively turning each carrier bacterium into a self-replicating archive of viral genetic material. Under normal conditions the prophage remains silent, allowing the carrier strain to colonize the gut without being lysed. When the carrier population encounters a susceptible target bacterium—or when conditions trigger prophage induction—the integrated phage can enter its lytic cycle, producing new virions that are then released directly into the intestinal environment.

This design has several consequences that make it attractive as a prophylactic strategy. First, because the phage genome is maintained by a replicating bacterial population, the viral payload is continuously renewed rather than passively decaying, which addresses the persistence problem that undermines conventional prophylactic dosing. Second, phage production occurs in situ, in the same compartment the pathogen will occupy, sidestepping the barriers that degrade or dilute phages delivered from outside. Third, the system couples phage release to the ecology of the gut itself: the carrier strain establishes, persists, and produces virions locally, creating a standing population of lytic phage that is already in position when a pathogen attempts to establish infection.

In the mouse experiments described in the paper, animals that received the prophage-encoding engineered bacteria before pathogen challenge were protected against enteric infection, with the released lytic phages suppressing the target pathogen in the intestine. The authors frame this as prophylactic lytic phage therapy achieved through a biological delivery system—combining the killing power of lytic phages with the persistence and localization of a colonizing bacterial carrier. The results, they argue, demonstrate that engineered prophage carriers can convert the gut itself into a manufacturing site for therapeutic phages.

The technical achievement rests on a set of design decisions that reflect the peculiar biology of temperate phages. A prophage must be stable enough not to spontaneously induce and destroy its own carrier population, yet inducible enough to produce virions on a useful timescale. The carrier strain must be able to colonize the mouse gut without causing harm, must not be eliminated by the resident microbiota, and must not itself become the target of the phage it carries. Immunity mechanisms—typically conferred by prophage-encoded repressors—keep the carrier protected from its own phage, while the phage’s host range determines which pathogens the released virions can attack. Balancing these constraints is the core engineering challenge, and the study’s success in mice suggests the authors found a workable equilibrium.

The work also speaks to a broader conceptual shift in phage therapy. Most clinical and preclinical phage programs treat phages as drugs: purified virus preparations, dosed and formulated like small molecules or antibodies. That paradigm has produced encouraging results in compassionate-use cases and early trials, particularly for antibiotic-resistant infections, but it inherits the pharmacological weaknesses of a self-replicating, target-dependent agent. The prophage-carrier approach instead treats the phage as part of a living system, embedded in a bacterial chassis that handles persistence, localization, and production. In this view, the therapeutic unit is not a vial of virus but an engineered member of the gut community.

That shift brings both opportunities and questions. Living carriers can be designed to respond to environmental cues, to carry multiple prophages against different pathogens, or to be genetically confined through auxotrophy or kill switches—features that are impossible with purified phage preparations. At the same time, releasing engineered organisms and their viral payloads into the gut raises ecological and regulatory questions that purified phages do not: how stably the carrier colonizes, whether the integrated prophage spreads horizontally to other bacteria, how the resident microbiota responds to chronic phage production, and how such a product would be evaluated by regulators accustomed to defined molecular drugs. The mouse data establish proof of principle; translating it will require answering these questions in more complex microbial communities and, eventually, in hosts whose guts differ substantially from those of laboratory mice.

The study also contributes to a growing literature on the natural role of prophages in gut ecology. Most bacteria in the mammalian intestine carry prophages, and induction of these elements under stress conditions is increasingly recognized as a driver of bacterial competition and microbiome dynamics. The engineered system described in Nature Microbiology essentially harnesses a natural phenomenon—prophage carriage and induction—for a therapeutic purpose, turning a widespread biological mechanism into a controllable intervention. Whether that intervention can be made safe, predictable, and generalizable remains to be seen, but the mouse results mark a concrete step toward phage therapies that are deployed not as doses but as residents.

For a field confronting the relentless spread of antibiotic resistance in enteric pathogens, the appeal of a prophylactic strategy is obvious. Preventing an intestinal infection before it establishes is easier, safer, and cheaper than treating one that has already taken hold, and phages offer a specificity that broad-spectrum antibiotics cannot match—killing the pathogen while sparing the rest of the community. By encoding that specificity in a colonizing bacterium, the new work proposes a way to keep the weapon loaded and in place until it is needed. If the approach survives the translational challenges ahead, prophage-encoding carriers could become a template for a new class of living, prophylactic antimicrobials designed to guard the gut against its most dangerous inhabitants.

Subject of Research: Engineering prophage-encoding bacteria as living carriers for prophylactic lytic phage therapy against enteric infection in mice

Article Title: Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice

Article References: Bataglioli, R. A., Baaziz, H., Avalos, H. F., Smith, L., Baker, Z. R., Makhlouf, R. J., da Silva Barreira, D., Kaur, H., Southard, T., & Hsu, B. B. (2026). Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02484-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02484-3

Keywords: bacteriophage therapy, prophage, engineered bacteria, enteric infection, gut microbiome, lytic phage, prophylaxis, mouse model, antimicrobial resistance, synthetic biology, Nature Microbiology, phage delivery

Salmonella Typhimurium is among the leading causes of foodborne gastroenteritis worldwide, and its monophasic variant—distinguished serologically by the absence of one of its two flagellar phases—has surged in prevalence across Europe, the Americas and Asia over recent decades. The lineage, which belongs to sequence type 34 and typically displays the antigenic formula 4,[5],12:i:-, has repeatedly been implicated in outbreaks linked to pork, poultry and processed foods. Yet despite its clear epidemiological importance, the genetic determinants that allowed this clone to outcompete its biphasic ancestor, the previously prevalent ST19 lineage, had remained uncertain. The new study set out to resolve that question at unprecedented scale.

The team’s comparative analysis of tens of thousands of genomes revealed a striking pattern: the expanding ST34 clone carried a frameshift mutation in dinB, the gene encoding a translesion DNA synthesis polymerase also known as DNA polymerase IV. The mutation, a deletion of a single thymine residue within a homopolymeric tract of seven thymidines near the 5′ end of the gene, introduces a premature stop codon that truncates the 39.7-kilodalton DinB protein to a nonfunctional fragment of roughly 1.9 kilodaltons. Because DinB is normally involved in bypassing damaged DNA templates and in generating genetic diversity under stress, its loss initially appears counterintuitive for a pathogen on the rise.

Functional experiments, however, demonstrated that the crippled polymerase has far-reaching downstream consequences. Transcriptomic profiling showed that the frameshift dinB mutation rewires the expression of flagellar genes, altering the balance between the two phase-one and phase-two flagellin systems that Salmonella uses to evade host immune detection. Specifically, the mutation led to transcriptional changes that favored retention of fliC, which encodes phase-one flagellin, and set the stage for the subsequent loss of fljB, the gene encoding phase-two flagellin. Western blot analyses confirmed that dinB-mutant strains displayed an increased proportion of cells expressing FliC, while in vitro motility assays showed that swimming ability was preserved despite the underlying genetic upheaval.

The physiological consequence of this reprogramming became apparent in infection models. Using transposon insertion sequencing and in vivo competition experiments in mice, the researchers found that the requirements for successful gut colonization shifted once fljB was lost. Genes that were dispensable, or even costly, in the ancestral background became essential or advantageous in the mutant context, and vice versa. The frameshift dinB strain carrying the fljB deletion outcompeted the previously prevalent biphasic ST19 lineage in the intestine, indicating that the combination of the polymerase defect and flagellin loss conferred a measurable competitive advantage within the host environment.

To move beyond correlation, the authors built a temporal evolutionary model that simulated the dynamics of four competing lineages: biphasic ST19, biphasic ST34, ST34 carrying the frameshift dinB, and monophasic ST34 carrying both the frameshift and the fljB deletion. The modeling demonstrated that the chronological order of the events matters critically. The dinB mutation had to precede the loss of fljB for the monophasic clone to expand as observed, and the simulated selection coefficients derived from the model were quantitatively consistent with selection estimates computed from real-world changes in genotype frequencies among human clinical isolates. Sensitivity analyses confirmed that the conclusion held regardless of the initial frequency of ST34, the presence or absence of spatial population structure, or the precise metric used to quantify selection.

This ordered dependency is what the researchers describe as a stepwise pathoadaptation model: a sequence of gene-loss events in which each deletion reshapes the genetic background so that the next loss becomes beneficial rather than deleterious. The concept echoes a growing recognition in microbial evolution that genome reduction can be a creative force. Recent work on Vibrio parahaemolyticus, for example, showed that wave succession within a pandemic clone was likewise driven by gene loss, and earlier studies documented how monophasic Salmonella Typhimurium microevolved during a prolonged epidemic in the United Kingdom. The new study, however, is notable for linking the ecological success of a zoonotic lineage to a specific, mechanistically validated chain of molecular events.

The broader implications extend to public health forecasting. If the emergence of major bacterial clones can depend on relatively simple, ordered mutational steps, then surveillance systems that monitor homopolymeric tracts and other mutation-prone loci may gain predictive power over which lineages are poised to expand. The study’s data resources—including genomic data deposited at the China National GeneBank Database, Enterobase and NCBI, transcriptomic data under accession GSE280131, proteomic data via PRIDE, and transposon-sequencing reads under BioProject PRJNA1347559—provide a substantial foundation for such efforts. The mathematical model code has also been made publicly available on GitHub, enabling other groups to test the generality of the sequential gene-loss framework in other pathogens.

At the same time, the work underscores how little of bacterial adaptation is driven by gene acquisition alone. Monophasic ST34 also carries traits such as copper resistance and heavy-metal tolerance that have been implicated in its persistence in livestock production environments, and antimicrobial resistance remains a defining feature of many circulating clones. But the new analysis places gene loss at the center of the lineage’s rise, reframing flagellar phase variation—a long-studied quirk of Salmonella biology—as a decisive axis of clonal competition. As the authors note, understanding the genetic factors facilitating the emergence of infectious diseases is critical, and this study delivers a concrete mechanistic answer for one of the most consequential zoonotic pathogens of the modern food system. The lesson is uncomfortable but clarifying: for bacteria, sometimes less is more, and the road to pandemic status can be paved by the genes a pathogen leaves behind.

Subject of Research: Stepwise gene loss driving the clonal expansion of monophasic Salmonella Typhimurium ST34

Article Title: Sequential gene loss promotes expansion of monophasic Salmonella Typhimurium ST34

Article References: Wu, X., Wang, T., Jia, C., Zhou, H., Li, Y., Baker, S., & Yue, M. (2026). Sequential gene loss promotes expansion of monophasic Salmonella Typhimurium ST34. Nature Microbiology. https://doi.org/10.1038/s41564-026-02483-4

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02483-4

Keywords: Salmonella Typhimurium, monophasic ST34, gene loss, dinB, flagellin, fljB, pathoadaptation, bacterial evolution, genomic epidemiology, foodborne pathogen, zoonotic disease, Nature Microbiology

The centerpiece of the study is an in vivo CRISPR interference, or CRISPRi, screening platform. Unlike traditional knockouts, which permanently delete genes and can be impractical at genome-wide scale, CRISPRi uses a catalytically dead Cas9 protein, dCas9, guided by hundreds of thousands of small RNA molecules to reversibly silence transcription of individual genes. Each bacterial cell in a massive pooled library carries a guide RNA targeting a specific gene, so the abundance of each variant after a period in the host serves as a direct readout of how important the silenced gene was for survival. If a gene is essential in the gut, cells whose guide suppresses it will dwindle in number; if it is dispensable, those cells persist. Gene fitness, measured by deep sequencing of guide RNA abundance with unique molecular identifiers to reduce noise, thus becomes a high-resolution functional reporter of adaptation.

To make the experiment tractable, the researchers colonized mice with OligoMM12, a defined minimal microbial community of twelve mouse gut strains. This gnotobiotic approach, building on earlier genome-guided designs of minimal microbiotas, provides a reproducible yet realistic ecological backdrop in which E. coli must compete with other residents for nutrients and space, without the overwhelming complexity of a conventional microbiome. The team introduced genome-wide CRISPRi libraries into three very different E. coli strains: MG1655, the classic laboratory K-12 derivative; CFT073, a uropathogenic strain; and LF82, an adherent-invasive E. coli, or AIEC, associated with Crohn’s disease. As the libraries circulated through the mice, sequencing revealed which genes each strain depended on under specific conditions.

The first major finding concerns diet. When mice were fed standard chow, a high-fiber diet, or a high-fat Western-style diet, the metabolic landscape facing E. coli changed dramatically, and the essential gene profile shifted with it. Genes required for growth on one diet were dispensable or even deleterious on another, confirming at functional-genomic resolution that what an animal eats directly rewrites the nutritional rules of the gut. The screen also exposed cross-feeding interactions, identifying genes whose loss was tolerated only because other members of the defined community supplied the missing metabolites. In this way the platform does more than list essential genes; it sketches the metabolic web that connects E. coli to its microbial neighbors, showing that the bacterium’s survival strategy is woven into the ecology of the whole community.

Comparing the three strains side by side revealed that there is no single genetic playbook for intestinal colonization. Although the core essential genomes overlapped, reflecting shared housekeeping functions, each strain displayed a distinct signature of requirements. The analysis highlighted divergent strategies in motility, stress response and respiration. MG1655, CFT073 and LF82 each relied on different subsets of genes to cope with bile, acidity, oxygen tension and immune pressures, consistent with the idea that genetic diversity across the E. coli species translates into fundamentally different ecological tactics. The results extend earlier transposon-insertion sequencing studies in enterohemorrhagic E. coli, K1 strains and other pathogens, but with the added precision and tunability that CRISPRi offers, since partial silencing can reveal dose-sensitive phenotypes that complete knockouts miss.

One of the most medically relevant strands of the study concerns AIEC LF82, a strain strongly enriched in the ileal mucosa of Crohn’s disease patients. When the researchers induced intestinal inflammation with dextran sulfate sodium, they found that LF82 preferentially colonized the small intestine in the inflammatory environment, and its genetic dependencies shifted accordingly. Genes tied to iron acquisition became more important, echoing the known biology of lipocalin 2 and neutrophil gelatinase-associated lipocalin, host proteins that sequester iron-bearing siderophores during inflammation. Respiratory genes also rose in prominence, in line with evidence that inflammation disrupts intestinal oxygen balance and creates new terminal electron acceptors that facultative anaerobes can exploit. The inflammatory gut, in other words, is a different nutritional world, and the screen captured that transformation in genetic terms.

Perhaps the most striking discovery involves a mobile genetic element. LF82 carries the Gally prophage, and the CRISPRi data revealed that this integrated virus plays an important role in modulating the strain’s fitness in the inflamed gut. Follow-up analyses quantified phage particle release and showed that the prophage’s influence on fitness differed between inflamed and healthy conditions, adding to growing evidence that prophages are not merely parasitic passengers but functional modulators of host physiology. Previous work has shown that phage integration can rewire the respiratory strategy of E. coli, and the new findings place the Gally element squarely within the colonization toolkit of a Crohn’s-associated pathobiont. The observation that phage production itself appears to be regulated, and blocked under some host-like conditions, underscores how finely tuned these relationships are.

Technically, the study sets a new benchmark for rigor. Gene-level calls were derived using MAGeCK with robust ranking aggregation and Benjamini-Hochberg false-discovery-rate correction across individual mice as biological replicates, and guide activity predictions were used to improve on-target performance, drawing on earlier CRISPR-dCas9 screening work in E. coli. Raw CRISPRi and 16S sequencing data are available through the Sequence Read Archive under accession PRJNA1293909, and processed log2 fold-change values, statistical results, analysis scripts and notebooks are shared through public repositories, allowing other groups to reproduce and extend the work. The authors acknowledge support from the European Research Council, the Agence Nationale de la Recherche, the Fondation pour la Recherche Médicale and the Swiss National Science Foundation’s NCCR AntiResist program.

The broader significance of the work extends well beyond E. coli. By demonstrating that gene fitness can serve as a quantitative sensor of the gut environment, the platform offers a way to probe intestinal conditions directly through the organisms that live there, effectively turning bacteria into living microsensors of diet, inflammation and microbial competition. For microbiome science, where correlational studies abound, this is a shift toward mechanism: every essential gene identified is a hypothesis about a nutrient, a stress or a host defense that can be tested. For medicine, the strain-specific genetic requirements of Crohn’s-associated AIEC and the role of the Gally prophage suggest new angles for interventions that disarm pathobionts without indiscriminately wiping out beneficial residents. As researchers refine gnotobiotic models and CRISPRi delivery, in vivo functional genomics of this kind could become a routine tool, mapping not just which microbes are present in the gut but precisely which molecular functions make them winners or losers in one of the most densely populated ecosystems in the mammalian body.

Subject of Research: In vivo CRISPRi functional genomics of Escherichia coli adaptation to the mouse gut

Article Title: In vivo CRISPRi screens reveal Escherichia coli functional adaptations in the mouse gut

Article References: Maire, A., Ortelli, M., Tkacz, E., Dehio, C., Chassaing, B., Sokol, H., Rolhion, N., & Bikard, D. (2026). In vivo CRISPRi screens reveal Escherichia coli functional adaptations in the mouse gut. Nature Microbiology. https://doi.org/10.1038/s41564-026-02471-8

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02471-8

Keywords: E. coli, CRISPRi, gut microbiome, Nature Microbiology, adherent-invasive E. coli, Crohn's disease, Gally prophage, gene essentiality, mouse model, OligoMM12, functional genomics, intestinal colonization